DEMOGRAPHICS

EPIDEMOLOGY
35% is non-communicable disease in which 14% is cardio-vascular and 2% diabetic,
NCDs 12%, Cancer 2% ,Chronic Respiratory Disease 2%, Injuries 10%,
where 55% Communicable, maternal, prenatal and nutritional conditions
 Increasing percentage of male patients compare to female found with cardio-
diabetic disease
 Lack of physical activity, high uses of alcohol and tobacco are the causes of NCD’s
 Sex ratio : 1.01 male(s)/female in Ro Congo
Mother mean age 19.7 Y
 Literacy 71.3% (age 15 and over can read and write)
0.28physicians/10,00 0population
1.3 hospital beds/1,000 population
 Life expectancy Male V/S Female – 63/66 Y
 Increase the NCD’s more with female as compare to male
 Obesity is more in female of population
 Number of essential NCD medicines reported as generally 2 of 10
 MAJOR HOSPITAL TOWN
Congo Brazaveille
1.Sino Congolese-
2.CHU Brazaveille
3.Kele kele
4. Talangai

Key spécialités cardio/Neuro/Gastro/Infectiolog /Gynaecolog/Medicine-with 66%

of physicians, 42% of allied health professionals, and 28% of hospital beds
located in Brazzaville, where 37% of the population lives of the country.

Congo Point Noir-

1. Loandjili,
2. Asic ,
3. Tie –Tie ,
4. Netco,
5. Ocean
6. General Hospital
7. CMS
Key specialities Cardio/Neuro/Gastro/ Infectiology /Gynécologie/Medicine
 PORTFOLIO SELECTION
• On the basis of demographic segmentation &
therapy cap we are working in following portfolio
for revenue generation and base building
ACUTE THERAPY CHRONIC THERAPY
CELEBID -100 AVAS 10
CELEBID -200 AVAS 20
GRAMOCEF -O 200
GRAMOCEF - O400
ESOFAG
DOLO 50
ALLERCET
XONADINE 120
XONADINE 180
LEVOBACT 500mg (1x10 s)
LEVOBACT 750mg (1x10 s)
PHYTORAL TABLETS
PHYTORAL OINTMENT
ORNILOX
FEROX SYP
FEROX CAP
IREX SYRP
 UNDERSTANDING OF CONGO
BUSINESS MODEL
Agency-
Prodipharma- Proprietor- Mr Anatole

Manager
( Prodipharma)
Mr Jerry

Yves Ghislain IPEMOUSSOUA DORIANA GRACIA

(Brazaveille)Micro Point Nore(Micro Labs)
Labs

Distribution- UB Pharm and Laborex

Primary v/s Secondary- Euro 3812 v/s 2917 in Oct’18
SOP for team has already in placed
Ornilox, Gramocef-O,Phytoral and Ferox Rx’s are increasing trend
 Avas Rx’s is constant